Visit the MediPharm Labs Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
TORONTO, July 18, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate from the Toronto Venture Exchange (“TSXV”) and list its common shares on the TSX under the symbol “LABS”.
We are thrilled to have qualified to uplist to the TSX. This is an important step for the MediPharm Labs team and our shareholders. We have achieved significant growth and strong performance since we first began trading last October to become a top revenue generating cannabis Company in Canada.
Patrick McCutcheon, Chief Executive Officer, MediPharm Labs
As we focus on executing an ambitious global growth strategy, this graduation will also allow us to expand our investor audience and improve the liquidity of our shares.
Final approval of the listing is subject to certain customary conditions which the Company intends to fulfill by July 23, 2019.
For fact-based information on MediPharm Labs, view the company’s sponsored Investor Dashboard.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.